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BACKGROUND AND PURPOSE
The glucagon-like peptide 1 (GLP-1) receptor performs an important role in glycaemic control, stimulating the release
of insulin. It is an attractive target for treating type 2 diabetes. Recently, several reports of adverse side effects following
prolonged use of GLP-1 receptor therapies have emerged: most likely due to an incomplete understanding of signalling
complexities.
EXPERIMENTAL APPROACH
We describe the expression of the GLP-1 receptor in a panel of modified yeast strains that couple receptor activation to cell
growth via single Gα/yeast chimeras. This assay enables the study of individual ligand–receptor G protein coupling
preferences and the quantification of the effect of GLP-1 receptor ligands on G protein selectivity.
KEY RESULTS
The GLP-1 receptor functionally coupled to the chimeras representing the human Gαs, Gαi and Gαq subunits. Calculation of
the dissociation constant for a receptor antagonist, exendin-3 revealed no significant difference between the two systems. We
obtained previously unobserved differences in G protein signalling bias for clinically relevant therapeutic agents, liraglutide
and exenatide; the latter displaying significant bias for the Gαi pathway. We extended the use of the system to investigate
small-molecule allosteric compounds and the closely related glucagon receptor.
CONCLUSIONS AND IMPLICATIONS
These results provide a better understanding of the molecular events involved in GLP-1 receptor pleiotropic signalling and
establish the yeast platform as a robust tool to screen for more selective, efficacious compounds acting at this important class
of receptors in the future.
Abbreviations
BETP, 4-(3-benzyloxyphenyl)-2-ethylsufinyl-6-(trifluoromethyl)pyrimidine; compound 2, 6,7-dichloro-2-methylsulfonyl-
3-N-tert-butylaminoquinoxaline; DPP-IV, dipeptidyl peptidase-IV; FDGlu, flurorescein-Di-β-D-glucopyranoside; GLP-1,
glucagon-like peptide-1; GPCR, G-protein coupled receptor
Introduction
The observation that a greater insulin response occurs follow-
ing oral glucose administration than with an equivalent i.v.
challenge leads to the proposal of the incretin effect
(McIntyre et al., 1964). Glucagon-like peptide-1 (GLP-1) is an
incretin released from the intestine following nutrient inges-
tion. GLP-1 acts to regulate blood glucose primarily through
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the stimulation of insulin release from pancreatic β-cells
(Baggio and Drucker, 2007). This insulinotropic action of
GLP-1 is mediated via activation of a classical seven trans-
membrane, GPCR, the GLP-1 receptor (see Alexander et al.,
2013). Due to its central role in glucose-induced insulin
release, the GLP-1 receptor has become a major focus for
therapeutic strategies to target type 2 (insulin-insensitive)
diabetes (Nauck, 2011).
In addition to insulin insensitivity, type 2 diabetic
patients display lowered GLP-1 concentrations and a
reduced ability to promote insulin secretion (Quddusi et al.,
2003). Administration of exogenous GLP-1 peptide potenti-
ates glucose-dependent insulin secretion and, importantly,
regulates the hyperglycaemia observed in these patients
(Holst and Seino, 2009). However, the active form of
GLP-1 [GLP-1 (7-36) amide] has a very short plasma half-life
of a few minutes, being rapidly cleaved by the serine pro-
tease dipeptidyl peptidase-IV (DPP-IV) to an inactive form
[GLP-1 (9-36) amide] (Mentlein et al., 1993). Several, DPP-
IV-insensitive peptide analogues to GLP-1, which act as
GLP-1 receptor agonists, have been developed to demon-
strate improved plasma half-life. These so-called mimetics,
exenatide and liraglutide have been approved for clinical
use in the treatment of type 2 diabetes (Scott et al.,
2013).
Despite the undoubted advantages that these mimetics
provide for immediate weight loss and in managing previ-
ously uncontrolled type 2 diabetes, a number of concerns
remain regarding their long-term use including an increased
risk of pancreatitis and cancer (Butler et al., 2013). Signifi-
cantly, despite having a high degree of sequence homology,
the different ligands display markedly different clinical effects
(Pabreja et al., 2014) leading to speculation of multiple GLP-1
receptor isoforms. However, these results could also be
explained by a combination of ligand-directed signalling bias
and the ability of the GLP-1 receptor to couple to multiple G
proteins. Combined, these observations highlight an incom-
plete understanding of the signalling pathways underlying
the GLP-1 receptor response. These concerns lead to the clas-
sification of the mimetics in ‘tier 2’ of the consensus algo-
rithm for initiation and adjustment therapy for the American
Diabetes Association and European Association for the Study
of Diabetes. This category is for ‘less well-validated’ treat-
ments and should therefore be used in patients as a last line
(Nathan et al., 2009). A better understanding of the signalling
responses modulated by the GLP-1 receptor is therefore
required to enable the more efficient design and use of these
therapies.
Most traditional assays used to date to investigate GLP-1
receptor activation can be influenced by crosstalk of the dif-
ferent signalling pathways. Here we report the use of a
simple, robust, Saccharomyces cerevisiae system in which
single GPCR-G protein couplings can be observed (Dowell
and Brown, 2002) to study the effect of G protein subunit on
GLP-1 receptor activation. Previous studies have highlighted
the robust nature of yeast signalling assays for determining
relative efficacies of agonists and affinity values for both ago-
nists and antagonists (Stewart et al., 2009). Further, the indi-
vidual nature of the GPCR-G protein coupling permits
identification of potential signalling bias in the absence of
competing G proteins and other GPCRs.
Using the yeast signalling assays, here we describe, for
the first time, the G protein bias profiles of the clinically
used GLP-1 mimetics. In addition, we have investigated
the ability of two small-molecule allosteric modula-
tors; compound 2 (6,7-dichloro-2-methylsulfonyl-3-N-tert-
butylaminoquinoxaline, Knudsen et al., 2007) and BETP
[4-(3-benzyloxyphenyl)-2-ethylsulfinyl-6-(trifluoromethyl)
pyrimidine] (Sloop et al., 2010) to modulate GLP-1 receptor
signalling. Our data provide direct evidence for multiple high
affinity couplings for all GLP-1 receptor agonists and estab-
lishes the yeast platform as a robust tool to screen for more
selective highly efficacious mimetic compounds in the future.
Methods
Constructs and DNA manipulation
cDNA constructs of the human GLP-1 receptor containing a
myc-tag was donated by Professor Patrick Sexton (Monash
University, Australia). cDNA for human GLP-1 receptors was
provided by Dr Graeme Wilkinson (AstraZenica, UK). cDNA
for the glucagon receptor (GCGR) was purchased from the
Missouri University of Science and Technology cDNA
Resource Centre (http://cdna.org). DNA manipulations were
performed using standard methods. Oligonucleotides were
supplied by Invitrogen. PCR amplification used FastStart Taq
polymerase (Roche Diagnostics, Burgess Hill, UK). All con-
structs were sequenced by GATC (GATC Biotech, London,
UK) prior to use.
Yeast growth media and transformations
General yeast procedures were performed as described previ-
ously (Dowell and Brown, 2002). Culture media used was rich
yeast peptone dextrose adenosine (YPDA) (for routine cell
growth) or synthetic dropout (SD) media lacking uracil or
histidine as appropriate. Yeast transformations were achieved
by using the lithium acetate/single-stranded DNA/
polyethylene glycol method as previously described (Gietz
and Schiestl, 2007).
Yeast strain construction
Production of S. cerevisiae dual reporter strains expressing chi-
meras of five C-terminal amino acids of human Gα protein
with the yeast GPA1, 1-467, (GPA1/Gα) has been described
previously (Brown et al., 2003). Mammalian GPCRs were
introduced into the yeast strains (MMY14, MMY24, MMY25
and MMY28) by cloning an expression cassette consisting of
the GAPDH promoter, the GPCR of choice and the CYC1
terminator sequence into pRS306 and integrated at the ura3
locus. Intergrants were selected upon their ability to generate
a β-galactosidase activity response above basal when
stimulated with 10 μM GLP-1 (7-36) amide or glucagon
as appropriate for the GPCR being studied. β-galactosidase
activity was measured as described previously (Dohlman
et al., 1995; Brown et al., 2000) using o-nitrophenyl-β-D-
galactopyranoside as a substrate. For chimeric strains that did
not initially appear to functionally couple (n = 16 isolates) to
GLP-1 receptors, expression of the receptor was confirmed
using immunoblotting.
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Yeast growth assay
GPCR activation was measured using an assay for yeast
growth adapted from Bertheleme et al. (2013). The strains
used contain the HIS3 gene under the control of the
pheromone-responsive FUS3 promoter. Receptor agonism
induces expression of the reporter gene enabling growth in
media lacking histidine (-HIS). Cell growth was determined
using FDGlu as a substrate, which is converted to fluorescein
by exoglucanase, an enzyme secreted by dividing yeast cells
(Dowell and Brown, 2009). Initially, cells were grown for 24 h
in SD media lacking uracil (-URA) at 30°C to select for only
those expressing the receptor. Then, in a change to other
documented examples of GPCRs expressed in these reporter
strains, cells were cultured, overnight at 30°C (following a 1
in 10 dilution) in SD-URA-HIS media to remove basal activity
and provide a larger signalling range to be detected upon
stimulation with agonists. Finally, the cultures were diluted
in SD-URA-HIS media, supplemented with FDGlu at a final
concentration of 20 μM, to an OD600 of 0.02. Fluorescein
signal was detected as an increase in fluorescence (excitation
wavelength = 485 nm, emission wavelength = 535 nm) as a
measure of growth. Different concentrations of ligands
(0.01 nM–100 mM) were added and yeast growth was meas-
ured using either a TECAN Infinite M200 microplate reader
(TECAN Ultra Evolution, Reading, UK) or a Mithras LB940
microplate reader (Berthold Technologies, Harpenden, UK)
for 20 h.
Membrane preparations and immunoblotting
Cultures, 200 mL, of yeast cells were grown in YPDA and
plasma membrane extracts prepared as described previously
(Ladds and Davey, 2000; Ladds et al., 2005b). Samples were
collected in 50 μL resuspension buffer (20% sucrose, 10 mM
Tris-HCl pH 6.8) and diluted 1:1 with 2× Laemmli sample
buffer containing 6 M urea (Ladds and Davey, 2000). Extracts
were heated to 37°C for 10 min before being subjected to
SDS-PAGE using the Nu-PAGE technology (Invitrogen). Fol-
lowing separation using SDS-PAGE, samples were transferred
to PVDF membrane using a semi-dry blotter. Western blotting
was performed using a GLP-1 receptor polyclonal antibody
(Abcam, Cambridge, UK) and a donkey anti-rabbit IgG HRP
conjugate (Amersham, International, Little Chalfont, UK) as
the secondary antibody. HRP activity was detected using
enhanced chemiluminescence reagents EZ-ECL (Geneflow,
Lichfield, UK) and visualized using a Syngene G:Box gel docu-
mentation system (Syngene, Cambridge, UK) as described in
Bond et al. (2013).
Cell culture and transfections
HEK293T cells were provide by Dr Jügen Müller (University of
Warwick) and cultured in DMEM (Invitrogen) supplemented
with 10% FCS and L-glutamine in a humidified 5% CO2–95%
air incubator at 37°C. Cells were transfected with Fugene 6
(Roche, Indianapolis, IN, USA) in accordance with the manu-
facturer’s instructions. Transfected cell lines were grown for
48 h enabling maximal expression before assaying.
cAMP accumulation assays
Growth medium was removed from the cells and replaced
with serum free DMEM containing 500 mM IBMX for
30 min. Peptides in the range 10 pM to 1 mM were added for
a further 15 min. Ice-cold ethanol (95–100% v v−1) was used
to extract cAMP, which was subsequently measured by radio-
receptor assay as previously described (Poyner et al., 1992).
Fluorescent microscopy of yeast
To visualize GLP-1 receptor expression in yeast cells, a
C-terminal in-frame fusion construct between the GLP-1
receptor and 3xmCherry ORFs fused together (separated by a
Asp-Gly linker) was generated using a two-step cloning tech-
nique as described previously (Ladds et al., 2005b). To gener-
ate an expression cassette, GLP-1 receptor-3xmCherry was
cloned into pRS306 containing the GAPDH promoter and the
CYC1 terminator sequence separated by a BamHI restriction
site. This was integrated at the ura3 locus. Positive transfor-
mants were grown in YPDA to a density of 5 × 106 cells mL−1.
Then 100 μL of culture was harvested and the cells washed in
growth media. Cell suspension (3 μL) was transferred to slides
(Sigma) and viewed using a Personal DeltaVision system
(Applied Precision, Issaquah, WA, USA) equipped with a Pho-
tometric CoolSNAP HQ camera (Roper Scientific, Trenton, NJ,
USA). Deconvolution was applied to images for visual clarity.
Data analysis
Data were analysed using Prism 6.0c (Graphpad Software, San
Diego, CA, USA). Concentration-response curves were fitted
using the three-parameter logistic equation to obtain EC50 and
Emax values. The operational model for partial agonism (Black
and Leff, 1983) was used to obtain values of efficacy (log τ) and
the equilibrium dissociation constant (log KA). These values
were then used to quantify signalling bias as change in log
(τ/KA) relative to the natural GLP-1 receptor ligand, GLP-1
(7-36) amide (Figueroa et al., 2009). Statistical differences were
analysed using one-way ANOVA with Bonferroni’s or Dunnett’s
multiple comparisons or Student’s test as appropriate and a
probability (P) < 0.05 was considered significant.
Materials
GLP-1 (7-36) amide, oxytomodulin, glucagon, exendin-4
(exenatide) and exendin-3 were synthesized by Alta Bio-
sciences (University of Birmingham, Birmingham, UK) and
prepared as 1 mM stocks in water. Liraglutide was supplied by
George Eliot Hospital NHS Trust (Nuneaton, UK). Small-
molecule agonists, compound 2 and BETP were obtained
from Sigma-Aldrich (St Louis, MO, USA) and prepared as
100 mM stocks in DMSO. Yeast nitrogen base and yeast
extract were purchased from Difco (Franklin Lakes, NJ, USA).
Flurorescein-Di-β-D-glucopyranoside (FDGlu) was purchased
from Invitrogen (Paisley, UK). All other reagents were pur-
chased from Sigma-Aldrich.
Results
The GLP-1 receptor can activate the
yeast-mating pathway via specific G
protein chimeras
Modification of the S. cerevisiae mating pathway to enable
functional coupling of mammalian GPCRs to the pheromone
BJPGlucagon-like peptide-1 receptor ligand bias
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response pathway has enabled the generation of a genetically
tractable system in which to express human receptors to
examine their signalling properties (Brown et al., 2000;
Stewart et al., 2009). These strains are deleted for the phero-
mone receptor, to provide a null background and contain a
dual reporter (FUS1-lacZ and FUS1-HIS3) gene under the
control of the endogenous yeast pheromone response to give
a quantitative assay for GPCR activation (Dowell and Brown,
2002).
The GLP-1 receptor, under the control of a strong yeast
promoter, was integrated into a panel of strains engineered to
contain chimeric Gα-subunits in which the 5 C-terminal
amino acids of GPA1 have been replaced with those of mam-
malian Gαs, Gαi, Gαz and Gαq. To determine which
Gα-subunits the GLP-1 receptor signals through, yeast strains
expressing the receptor were incubated with 10 μM of the
potent, natural peptide ligand, GLP-1 (7-36) amide (hereafter
referred to as GLP-1 for simplicity). An increase in reporter
gene activity was observed when the G protein chimeras
corresponding to Gαs, Gαi and Gαq were present, confirming
that the receptor is functionally expressed in the yeast system
and can couple to the pheromone response pathway
(Figure 1A). Signalling was not observed via the un-modified
GPA1 or Gαz subunits (n ≥ 16 isolates were screened for
functionality). To ensure uniform expression across all yeast
strains, cells were grown to mid log phase and cell extracts
obtained before immunobloting using a GLP-1 receptor anti-
body (Figure 1B). Finally, efficient trafficking of the GLP-1
receptor was confirmed using a modified receptor engineered
to contain 3mCherry fluorophores at the C-terminus
(Figure 1C). Addition of the fluorophore to the C-terminus of
the GLP-1 receptor did not alter the coupling profile of the
receptor but confirmed plasma membrane localization in all
strains.
GPCR specificity for individual yeast chimeras has previ-
ously been demonstrated to generally conform to that
observed in mammalian cells, indeed the GLP-1 receptor has
been reported to couple through Gαs, Gαi and Gαq in other
systems (Baggio and Drucker, 2007). We next compared
the pharmacology of the GLP-1 receptor with respect to
GPA1/Gαs activation in yeast cells and accumulation of
cAMP in transiently transfected HEK293T cells. Initially,
concentration-response curves were constructed to the GLP-1
receptor agonist, GLP-1, in both yeast and mammalian cells
expressing the receptor (Figure 2A and B). Sigmoidal dose-
response curves were observed allowing the calculation of an
EC50 value for GLP-1 (10 nM and 150 pM, yeast and mamma-
lian assays respectively). Notably, the agonist was more
potent for the accumulation of cAMP than in the yeast
system; however, both responses were robust over five repeats
with minimal error (Table 1).
To ensure faithful transfer of GLP-1 receptor pharmacol-
ogy between mammalian cells and the yeast system, interac-
tion experiments were performed using the antagonist
exendin-3 (Göke et al., 1993). Increasing concentrations of
exendin-3 inhibited the response to GLP-1 in both systems
Figure 1
Activation of the yeast-mating pathway by the GLP-1 receptor. (A) Strains containing the GLP-1 receptor were stimulated with 0 or 10 μM GLP-1
for 20 h and assayed for activation of the FUS1 > lacZ reporter gene. Data are mean of five independent experiments ± SEM. Data were determined
as significantly different from the non-peptide response using Student’s t-test where **P < 0.01, ***P < 0.001. (B) Expression of the GLP-1 receptor
in yeast strains containing various GPA1/Gα chimeras was confirmed using immunoblotting. (C) A C-terminal 3xmCherry tag was engineered onto
the GLP-1 receptor and expression at the plasma membrane was confirmed using fluorescence microscopy. Scale bar = 10 μm.
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causing a dose-dependent rightward shift in the GLP-1
response and substantial depression of Emax (Figure 2C and D).
Double reciprocal plots of equiactive concentrations of GLP-1
in the presence and absence of exendin-3 at 10 nM (Figure 2E
and F) were constructed to calculate the dissociation constant
for the receptor-antagonist complex (KB) (Gaddum et al.,
1955). These values did not differ significantly between the
two assay systems (Table 1). Despite the reduction in ligand
Figure 2
The GPA1/Gαs responses reproduce cAMP data for GLP-1 receptor agonism. (A) Dose-response curves to the natural GLP-1 receptor agonist,
GLP-1, were constructed in the yeast strain containing the GPA1/Gαs chimera. Activation of the reporter gene was calculated as a percentage of
the maximum response observed. (B) cAMP accumulation was determined following 30 min stimulation of transiently transfected HEK293T cells
and expressed as a percentage of the maximum observed. (C) S. cerevisiae containing the GPA1/Gαs chimera and (D) transiently transfected
HEK293T cells were stimulated with GLP-1 in the presence of the indicated concentrations of exendin-3. All data are expressed as a percentage
of the maximal response in the absence of inhibitor and are mean of 5–8 independent experiments ± SEM. (E) and (F) Double reciprocal plots
for GLP-1 in the presence (Y axis) and absence (X axis) of 10 nM exendin-3.
BJPGlucagon-like peptide-1 receptor ligand bias
British Journal of Pharmacology (2014) 171 3651–3665 3655
potency, these data demonstrate that the pharmacology of
the GLP-1 receptor in the yeast system broadly replicates that
of mammalian cells, thereby establishing a useful platform
for the investigation of G protein coupling in isolation from
crosstalk between pathways.
Using the yeast system to investigate
competing GLP-1 receptor G protein pathways
Significantly, we identified in Figure 1 several functional
GLP-1 receptor-G protein couplings that in mammalian cells
act to regulate second messengers that can be assayed to
determine receptor pharmacology. Of particular note, the
primary physiological role of the GLP-1 receptor is to stimu-
late insulin secretion through the regulation of intracellular
cAMP concentrations (Seino, 2012). GPCR-mediated control
of cAMP levels occurs via regulation of adenylate cyclase
activity, both positively (via Gαs) and negatively (via Gαi).
The potential competing nature of the GLP-1 receptor cou-
plings identified (Figure 1) highlight difficulties in the ability
to use traditional mammalian assays to differentiate the pro-
portion of a response attributable to each pathway. The
effect of these two G proteins on GLP-1 receptor pharma-
cology was therefore focused upon for the remainder of this
study.
To compare the effect of the G protein subtype on recep-
tor activation, concentration-response curves were con-
structed to the GLP-1 receptor agonist, GLP-1 in S. cerevisiae
strains containing either the Gαs or Gαi GPA1 chimeras
(Figure 3A). The agonist was more potent when the receptor
was coupled to GPA1/Gαs as could be seen through inspec-
tion of the values in Table 1. There was also a significant (P <
0.01, n = 5) reduction in the maximal response when the
receptor coupled to the inhibitory G protein chimera.
An equimolar bias plot was generated (Rajagopal et al.,
2011) to demonstrate the influence of the G protein subunit
on ligand activity (Figure 3B). This graph enabled potential
signalling preferences of ligands for individual pathways to
be identified easily. The normalized responses for the differ-
ent G protein chimeras at each concentration of GLP-1 were
replotted against each other highlighting the preference of
the receptor for GPA1/Gαs activation when stimulated with
GLP-1.
To further investigate the signalling properties of the
GLP-1 receptor in the chimeric yeast strain containing the
GPA1/Gαi subunit, interaction experiments were performed
using the antagonist, exendin-3. Similar to the observations
in the GPA1/Gαs strain (Figure 2C), incubation with increas-
ing concentrations of the antagonist resulted in a rightward
shift of the GLP-1 dose-response curves (Figure 3C) decreas-
ing the potency and maximal responses demonstrating
an insurmountable effect. The dissociation constant for
the antagonist, calculated from a double reciprocal plot
(Figure 3D), did not differ significantly from that calculated
in the presence of the GPA1/Gαs subunit (Table 1) suggesting
that antagonism of the GLP-1 response by exendin-3 is inde-
pendent of the G protein subunit.
Investigating ligand bias of endogenous
GLP-1 receptor agonists
In addition to GLP-1, tissue-specific, post-translational pro-
cessing of pro-glucagon produces both glucagon and the
highly similar, oxyntomodulin (Schepp et al., 1996). Gluca-
gon acts in opposition to insulin to promote glycogen break-
down thereby increasing blood glucose. Despite this, both
glucagon and oxyntomodulin have been demonstrated to act
via the glucagon receptor and the GLP-1 receptor to affect
intracellular concentrations of cAMP (via Gαs and Gαi). To
confirm that oxyntomodulin and glucagon were functional
at receptors expressed in the yeast system, we first tested
them at the glucagon receptor. Both glucagon and oxynto-
Table 1
Potency (pEC50) and maximal agonist response (Emax) in the presence of the GLP-1 receptor antagonist, exendin-3
[Exendin-3] (M)
cAMP GPA1/Gαs GPA1/Gαi
pEC50a Emaxb pEC50a Emaxb pEC50a Emaxb
Vehicle 10.2 ± 0.1*** 100 ± 4.3*** 7.9 ± 0.1 100 ± 9.0*** 7.3 ± 0.07* 100 ± 9.2***
1 ± 10−11 10.1 ± 0.1*** 100 ± 5.7*** 7.8 ± 0.1 100 ± 9.2*** 6.9 ± 0.1* 100 ± 8.1***
1 ± 10−8 9.2 ± 0.1*** 61.7 ± 6.2*** 7.6 ± 0.2 68 ± 7.1*** 6.8 ± 0.2* 81 ± 7.1***
1 ± 10−6 8.9 ± 0.1*** 49.5 ± 7.1*** 7.3 ± 0.4 23 ± 7.0*** 6.7 ± 0.1* 42 ± 5.9***
cAMP GPA1/Gαs GPA1/Gαi
Slopec pKBd Slopec pKBd Slopec pKBd
1 ± 10−8 0.5 ± 0.005 7.9 ± 0.1 0.5 ± 0.006 7.8 ± 0.1 0.13 ± 0.006 7.9 ± 0.1***
Values generated through fitting of a three-parameter logistic equation and represent the mean ± SEM from five independent experimental
repeats.
aThe negative logarithm of the agonist concentration required to generate half the maximal response.
bThe maximal response to the ligand expressed as a percentage of that obtained in the absence of antagonist.
cSlope of linear regression from double reciprocal plot of GLP-1 in the presence and absence of 10 nM exendin-3.
dThe negative logarithm of the equilibrium disassociation constant for the antagonist calculated using the method of Gaddum et al., 1955.
Statistical significance compared with vehicle (*P < 0.05, **P < 0.01; ***P < 0.001) was determined by one-way ANOVA with Dunnett’s post-test.
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modulin activated the glucagon receptor in a yeast strain
containing either the GPA1/Gαs or GPA1/Gαi chimeras with
similar potencies (Figure 4A and B, Table 2). Significantly,
however, it is thought that oxyntomodulin, differing from
glucagon only through an eight-amino acid C-terminal
extension, exerts its affects, in mammalian cells primarily via
the GLP-1 receptor, acting to reduce food intake in humans
(Wynne et al., 2005; Schepp et al., 1996).
To further investigate the pharmacology of these ligands
at the GLP-1 receptor in isolation from competing pathways,
we next studied the ability of glucagon and oxyntomodulin
to activate the yeast-mating response via the GPA1/Gαs and
GPA1/Gαi chimeras. Both glucagon and oxyntomodulin
caused a dose-dependent activation of the reporter gene
(Figure 5A and B) with reduced potency compared with
GLP-1 (Table 3). Both peptides displayed different signalling
profiles relative to GLP-1 depending upon the G protein
chimera present. Glucagon appears to be a weak (EC50 =
300 nM) agonist with respect to GPA1/Gαs activation possi-
bly displaying only partial agonism with a significantly (P <
0.01, n = 5) reduced Emax (48.7 ± 6.6). However, a full, more
potent (EC50 = 102 nM) response in the presence of GPA1/Gαi
was observed (Table 3). Both oxyntomodulin and glucagon
demonstrate signalling bias for the activation of the GPA1/
Gαi chimera (Figure 5C). Differences in the log(τ/KA) ratios
relative to GLP-1 indicated that both ligands display a signifi-
cant (P < 0.01, n = 5) bias towards the inhibitory G protein
(Figure 5D). These data provide an insight into the molecular
mechanisms affected by GLP-1 receptor agonism and a pos-
sible explanation for the reduced potency of the glucagon
ligands observed in mammalian cAMP assays (Jorgensen
et al., 2007).
Using the yeast system to investigate
synthetic small-molecule GLP-1
receptor agonists
GLP-1 receptor agonism in human islets promotes insulin
release (Seino, 2012); it has therefore become an increasingly
Figure 3
The G protein chimera influences the activity profile of GLP-1 receptor agonist. (A) Dose-response curves to the natural GLP-1 receptor agonist,
GLP-1 were constructed in strains containing the GPA1/Gαs or GPA1/Gαi chimera. Activation of the reporter gene was calculated as a percentage
of the maximum response observed in the GPA1/Gαs strain. (B) Equimolar comparison of bias, the normalized response at equivalent
concentrations of agonist for each G protein chimera shown in (A) was plotted to allow visualization of any pathway preference. Dashed line
represents no bias. (C) GPA1/Gαi chimera strain was stimulated with GLP-1 in the presence of the indicated concentrations of exendin-3. Reporter
gene activity was determined following 20 h stimulation. All data are expressed as a percentage of the maximal response in the absence of
inhibitor and are mean of 5–8 independent experiments ± SEM. (D) Double reciprocal plot for GLP-1 in the presence (Y axis) and absence (X axis)
of 10 nM exendin-3.
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attractive target for the treatment of type 2 diabetes. Several
orally active, non-peptidyl agonists of the GLP-1 receptor
have been described including the substituted quinoxaline,
compound 2 (Knudsen et al., 2007) and the pyrimidine-
based, BETP (also termed compound B, Sloop et al., 2010).
These molecules have been shown to bind to the receptor in
allosteric sites each having differing agonist affects on GLP-1
receptor-mediated cAMP accumulation (Knudsen et al., 2007;
Sloop et al., 2010).
Both compound 2 and BETP induced a dose-dependent
increase in reporter gene activity following GLP-1 receptor
stimulation (Figure 6A and B). The compound 2-induced
response was significantly (P < 0.01, n = 6) influenced by the
G protein chimera present displaying a reduced maximal
response (Table 4) when coupled to the inhibitory pathway.
In contrast, BETP agonism was not significantly (P > 0.05)
affected by the G protein with EC50 values of 10 nM and
15 nM (Gαs and Gαi, respectively), this was confirmed
through construction of an equimolar bias plot where the
BETP data did not deviate from the no-bias line of unity
(Figure 6C). These results provide a possible explanation for
the observation that BETP displays partial agonism for GLP-1
receptor-mediated cAMP production in mammalian systems
(Wootten et al., 2012) and demonstrate an intriguing insight
into differences between the signalling of the two non-
peptide ligands.
GLP-1 long-lasting mimetics display differing
signalling profiles
GLP-1 is rapidly broken down by peptidases in the body and
a reduction in circulating peptide is observed in diabetic
patients. Therefore, an alternative therapeutic approach has
been to develop longer lasting peptides to prolong insulin
secretion, reducing blood glucose levels in patients with Type
2 diabetes. While these injectable peptides have significant
sequence homology to the natural GLP-1 agonist (liraglutide:
97% and exenatide: 53%, Figure 7A), both are relatively
resistant to peptide degradation and have been approved as
treatments by the US Food and Drug Administration.
However, both have been associated with adverse side effects
Figure 4
Functional coupling of the glucagon receptor to GPA1/Gαs and GPA1/Gαi. Dose-response curves to glucagon and oxyntomodulin at the glucagon
receptor were constructed in yeast strains containing (A), the GPA1/Gαs and (B), the GPA1/Gαi chimera. Activation of the reporter gene was
calculated as a percentage of the maximum response observed.
Table 2
Potency (pEC50) and maximal response (Emax) values for peptide agonists of the glucagon receptor in yeast assays
Ligand
GPA1/Gαs GPA1/Gαi
pEC50a Emaxb pEC50a Emaxb
Glucagon 8.0 ± 0.1 101 ± 6.1 8.0 ± 0.3 98 ± 8.1
Oxyntomodulin 7.8 ± 0.2 85 ± 10.4 7.6 ± 0.2 85 ± 6.8
Values generated through fitting of a three-parameter logistic equation and represent the mean ± SEM from at least five independent
experimental repeats.
aThe negative logarithm of the agonist concentration required to generate half the maximal response.
bThe maximal response to the ligand expressed as a percentage of that obtained in the absence of antagonist.
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and do not exhibit the same affects in clinics (Anderson and
Trujillo, 2010; Franks et al., 2012; Singh et al., 2013).
Both liraglutide and exenatide induced dose-dependent
activation of the yeast-mating pathway via agonism of the
GLP-1 receptor (Figure 7B and C). However, when coupled to
the stimulatory GPA1/Gαs chimera, exenatide displayed a
significantly (P < 0.001, n = 5) reduced EC50 compared with
both GLP-1 and liraglutide (Table 3). Application of the
operational model for partial agonism yielded log KA (−6.4 ±
0.4 and −6.3 ± 0.4) and log τ (0.9 ± 0.3 and −0.02 ± 0.3) values
for liraglutide and exenatide, respectively, further suggesting
that the former acts as a partial agonist. In contrast, when
coupled to the inhibitory G protein chimera, GPA1/Gαi
similar potencies (Table 3) and log τ (0.5 ± 0.5 and 0.5 ± 0.4)
values were obtained for both mimetics suggesting that the
ligand responses are influenced by the G protein subunit
present, this was further demonstrated through the genera-
tion of equimolar bias plots of the data (Figure 7D). Calcula-
tion of log(τ/KA) ratios relative to the natural agonist
confirmed that liraglutide displays no change in signalling
bias relative to GLP-1. However, exenatide preferentially sta-
bilizes the GLP-1 receptor-GPA1/Gαi interaction (Figure 7E).
To our knowledge, this is the first report of these differences
in the pharmacology between the peptide ligands of the
GLP-1 receptor and may provide valuable mechanistic insight
into clinical observations.
Discussion
Here we report the use of the S. cerevisiae system to isolate the
individual signalling pathways, which, in human cells, are
involved in GLP-1 receptor-mediated regulation of cAMP.
Although a reduced potency of the natural ligand, GLP-1 was
observed relative to that generated from HEK 293T cell cAMP
accumulation; the yeast system is a valid platform from
which to study GLP-1 receptor pharmacology with antago-
nism of the response faithfully reproduced. We therefore
sought to use this system to investigate the molecular phar-
macology of several GLP-1 receptor ligands including
Figure 5
Activation of the GLP-1 receptor by glucagon and oxyntomodulin. (A) Yeast strains expressing the GLP-1 receptor were stimulated with GLP-1,
glucagon or oxyntomodulin for 20 h and reporter gene activity determined following coupling of the receptor to (A) the GPA1/Gαs or (B) the
GPA1/Gαi chimera. Data are expressed as a % of the maximum response achieved by GLP-1 in the GPA1/Gαs strain. (C) The normalized responses
for equivalent concentrations of each ligand were plotted to observe the relative G protein bias where the dashed line represents no bias. (D)
Signalling bias was calculated relative to GLP-1 as the change in log(τ/KA) ratio for the data in (A) and (B). Data were determined as statistically
different (**P < 0.01, ***P < 0.001) from GLP-1, using a one-way ANOVA with Bonferroni’s post-test. All data are mean of 5–8 independent
experiments ± SEM.
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clinically relevant peptide mimetics and small-molecule
allosteric compounds.
The advantage of yeast over other systems is the relatively
null background for G protein activation and therefore the
ability to observe individual activation profiles. The GLP-1
receptor, like many other GPCRs, has been documented to
display coupling to numerous G proteins. Primarily, it acti-
vates the Gαs subunit to stimulate cAMP production;
however, other responses including pertussis toxin-sensitive,
inhibitory Gαi couplings have been observed (Montrose-
Rafizadeh et al., 1999; Hallbrink et al., 2001), although these
responses have been poorly characterized (Coopman et al.,
2010). Using the yeast chimeric Gα system (Dowell and
Brown, 2002), we were able to identify functional GLP-1
receptor coupling to the inhibitory G protein. The natural
peptide ligand (GLP-1) promoted dose-dependent activation
of the GPA1/Gαi chimera with significantly (P < 0.05) reduced
potency (EC50, Table 3) and efficacy (log τ, Table 3) compared
with signalling via GPA1/Gαs. However, antagonism of the
response was unaffected. These data suggest that the G
protein subunit present does not affect antagonist affinity
and therefore any changes in agonist affinity observed are
probably a result of G protein preference and not simply
a consequence of the assay system. The yeast signalling
platform has enabled us to investigate the potential for
ligand-directed G protein signalling bias at the GLP-1
receptor.
While several studies have investigated the effect of dif-
ferent ligands on the biasing of GLP-1 receptor signal trans-
duction via calcium (Gαq-mediated) or ERK pathways (Koole
et al., 2010), little has been reported for the inhibition of
cAMP production. Since adverse side effects from the use of
the GLP-1 mimetics could be attributed to previously uniden-
tified off-target signalling events, we next used the yeast
system to investigate ligand-induced signalling bias of other
GLP-1 receptor ligands (Figure 8). The glucagon agonists,
oxyntomodulin and glucagon successfully activated both the
stimulatory and inhibitory G protein pathways via the GLP-1
receptor. However, both ligands displayed significant (P <
0.001, n = 5) bias towards Gαi. Similarly, the GLP-1 mimetic
exenatide preferentially activated the inhibitory subunit. In
contrast, only a small change in bias profile from the natural
agonist was observed when liraglutide was used. Despite dif-
ferences in peptide sequence primarily occurring at the
C-terminus, with the exception of liraglutide, all ligands
demonstrated a significant (P < 0.05, n = 5) degree of Gαi bias
relative to the GLP-1. These data offer an intriguing insight
into the mechanism by which peptide ligands activate family
B receptors. Previous models suggest that the C-terminus is
solely responsible for receptor binding to facilitate interac-
tion of the N-terminus, which promotes activation (Hoare,
2005). Our results suggest that the C-termini of the peptides
are primarily responsible for affecting the G protein prefer-
ence of the activated receptor. However, given that the only
peptide ligand tested that did not show a Gαi bias (liraglu-
tide) also had the most highly conserved N-terminus, we
cannot exclude the possibility that the N-terminus also plays
a role in receptor signalling.
In addition to peptide ligands, the yeast system was used
to investigate the signalling properties of two small-molecule
allosteric compounds (compound 2 and BETP). In contrast to
cAMP assays (Sloop et al., 2010), both ligands activated GLP-1
receptor-GPA1/Gαs with similar potencies. However, com-
pound 2 displayed a significant reduction in maximal
response when coupled to the Gαi chimera that was not
observed when BETP was used. These data may provide an
explanation for the observed differences in GLP-1 receptor
agonism by the two allosteric compounds when cAMP pro-
duction is measured (Sloop et al., 2010).
Multiple glucagon-related receptors have been implicated
in glycaemic control, all of which couple to several G protein
subunits. The ability of ligands to differentially activate
specific G protein pathways following receptor stimulation
has been a noted property for GPCRs for many years
(Kenakin, 1995). Differential activation of these pathways
including receptor internalization, Ca2+ signalling and cAMP
regulation by ligands, results in distinct physiological
responses. The yeast system enables investigation of
Table 3
Potency (pEC50), affinity (pKA) and coupling efficacy (log τ) values for various GLP-1 receptor agonists from yeast assays
Ligand
GPA1/Gαs GPA1/Gαi GPA1/Gαs GPA1/Gαi
pEC50a Emaxb pEC50a Emaxb pKAc log τd pKAc log τd
GLP-1 8.1 ± 0.10*** 100 ± 5.4*** 7.5 ± 0.1 75.7 ± 5.6 6.7 ± 0.2** 1.0 ± 0.2** 6.7 ± 0.3 0.7 ± 0.2
Glucagon 6.5 ± 0.40*** 48.7 ± 6.6*** 6.9 ± 0.5 82.6 ± 8.0 6.2 ± 0.2** −0.1 ± 0.3** 6.4 ± 0.3 0.4 ± 0.2
Oxyntomodulin 6.7 ± 0.20*** 103 ± 7.2*** 7.7 ± 0.3 76.6 ± 7.0 5.4 ± 0.2** 1.3 ± 0.01** 6.8 ± 0.4 0.3 ± 0.1
Exenatide 6.5 ± 0.07*** 53.6 ± 8.0*** 6.6 ± 0.2* 87.7 ± 5.4 6.3 ± 0.4** −0.02 ± 0.3** 6.2 ± 0.6 0.5 ± 0.4
Liraglutide 7.5 ± 0.06*** 99.1 ± 7.9*** 7.1 ± 0.06 84.6 ± 5.3 6.4 ± 0.4** 0.9 ± 0.3** 6.5 ± 0.7 0.5 ± 0.5
All values are mean ± SEM of five independent experimental repeats. Statistical significance compared with GLP-1 (*P < 0.05; **P < 0.01;
***P < 0.001) was determined by one-way ANOVA with Dunnett’s post-test.
aThe negative logarithm of the agonist concentration required to produce a half-maximal response.
bThe maximal response to the ligand expressed as a percentage of that obtained in the absence of antagonist.
cThe negative logarithm of the equilibrium disassociation constant for each ligand generated through use of the operational model of agonism
(Black and Leff, 1983).
dτ is the coupling efficiency parameter, generated by comparison to the natural ligand, GLP-1 using the operational model of agonism.
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Figure 6
Activation of the GLP-1 receptor by non-peptide ligands. Yeast strains expressing the GLP-1 receptor containing either the GPA1/Gαs or GPA1/Gαi
chimera stimulated with a range of (A), compound 2 or (B), BETP concentrations for 20 h and reporter gene activity determined. Data expressed
as a percentage of the maximum response achieved through activation of GPA1/Gαs. (C) To observe pathway preferences for each ligand, the
normalized responses for equivalent concentrations of ligand were used to generate an equimolar bias plot; the dashed line represents no bias.
All data are mean of five independent experiments ± SEM.
Table 4
Potency (pEC50) and maximal response (Emax) values for non-peptide agonists of the GLP-1 receptor in yeast assays
Ligand
GPA1/Gαs GPA1/Gαi
pEC50a Emaxb pEC50a Emaxb
Compound 2 8.6 ± 0.2 100 ± 7.3 8.5 ± 0.3 67.5 ± 7.3**
BETP 8.1 ± 0.2 100 ± 5.1 7.8 ± 0.2 96.5 ± 4.3
All values determined through fitting of a three-parameter logistic equation and are mean ± SEM of five independent experimental repeats.
Statistical significance was determined using Student’s t-test.
**Emax GPA1/Gαi different (P < 0.01) from Emax GPA1/Gαs.
aThe negative logarithm of the agonist concentration required to generate half the maximal response.
bThe maximal response to the ligand expressed as a percentage of that obtained in the absence of antagonist.
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Figure 7
The influence of G protein subtype on GLP-1 receptor activation by peptide drugs used in the treatment of type 2 diabetes. (A) Sequence
homology of GLP-1 mimetics. Blue circles are conserved throughout all three peptides, orange circles are unique to liraglutide and red denotes
exenatide residues. The DPP-IV cleavage site is indicated by the dashed line. (B, C) Concentration-response curves were constructed to each of
the GLP-1 receptor agonists in the indicated yeast strains. Each strain was assayed for reporter gene activity following incubation with a range of
ligand concentrations for 20 h. Data are presented as the % maximal response achieved by GLP-1 at the GPA1/Gαs chimera strain. (D) Equimolar
bias comparison generated by plotting the normalized responses at each G protein chimera for equivalent concentrations of ligand. Dashed line
represents no bias. (E) The signalling bias was determined for each drug relative to the natural agonist using the change in log(τ/KA) ratio for the
data in (B) and (C). Statistical significance was determined using one-way ANOVA with Bonferroni’s post-test with each data set compared with
GLP-1 (***P < 0.001). All data are mean of 5–8 independent experiments ± SEM.
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individual receptor-Gα subunit interactions and therefore
provides a simple, robust assay to identify compounds that
affect particular pathways. Here we have reported the func-
tional expression of two glucagon-related receptors, which
act in opposition to regulate blood glucose levels. Interest-
ingly, a number of naturally occurring ligands (glucagon and
oxyntomodulin) have been documented to activate both the
glucagon receptors and the GLP-1 receptor (Jorgensen et al.,
2007). However, each of the different ligand–receptor combi-
nations displays a distinct G protein bias profile. It has been
suggested that it may be beneficial to generate so-called
hybrid peptides, which could modulate the activity of both
receptors (in different ways) simultaneously (Cho et al.,
2012). For example, a peptide that functioned as an agonist
for GLP-1 receptor-Gαs while antagonizing the glucagon
receptor-Gαs could have enormous therapeutic potential.
Selecting compounds that differentially regulate the G
protein pathway activated by each receptor could have a
similar effect. For example, a molecule, which activates GLP-1
receptor-Gαs and also glucagon receptor -Gαi, would appear
to antagonize the latter’s cAMP response. The observations in
this manuscript that the simple yeast-screening platform can
not only be used to screen for receptor activation but also to
detect ligand-directed G protein-signalling bias for these
receptors demonstrates that it has the potential to be used in
the rapid identification of such compounds.
The GLP-1 receptor not only regulates the release of
insulin, but it has also been implicated in a host of other
clinical contexts including cardioprotective and satiety
effects (Pabreja et al., 2014). It is thought that these effects are
mediated from different tissues. Indeed, the GLP-1 receptor
has been isolated from multiple tissues including lung, brain,
stomach and heart (reviewed Cho et al., 2012). Several reports
have noted that GLP-1 receptors display tissue-specific phar-
macology (reviewed Pabreja et al., 2014) leading to the sug-
gestion of a second GLP-1 receptor subtype; however, this
has not been identified. Given our observations of ligand-
directed G protein signalling bias, it is tempting to speculate
that these multiple receptor subtypes could result from tissue-
specific GLP-1 receptor-G protein couplings. For example,
activation of the GLP-1 receptor inhibits the release of gastric
acid release thereby delaying gastric emptying. The mecha-
nism by which this occurs has not been fully elucidated;
however, there is some suggestion that it is pertussis toxin-
sensitive Gαi coupling (Schepp et al., 1992). A systematic
review of cell type-specific GLP-1 receptor signal transduction
has not, to date, been undertaken in particular with reference
to responses mediated via different G protein subunits, which
would be needed to provide clarity. Given the wide range of
off-target side effects reported from the use of the clinically
prescribed drugs and our data indicating their distinct G
protein bias profiles, not only Gαs pathways should be con-
sidered but also those responses mediated through Gαi in
each tissue.
The data we have described demonstrate the powerful
ability of the yeast assay to observe, for the first time,
system-independent, pharmacological properties of poten-
tial therapeutic agents. Both the glucagon receptor and the
GLP-1 receptor are members of the secretin (family B, class
2) receptor family, which contains 15 GPCRs. These GPCRs
typically bind peptide ligands that range in size from 27 to
84 amino acids. Consequently, for many years, there was
reluctance from researchers to explore these receptors in
yeast due to the presence of the yeast cell wall. It was argued
that peptides would be restricted in their ability to permeate
the cell wall so preventing activation of the GPCR. We have
previously reported the expression of two corticotropin-
releasing factor receptor subtypes in yeast (Ladds et al., 2003;
2005a), while the functional co-expression of the calcitonin
receptor-like receptor with various receptor activity modify-
ing proteins (RAMPs) has also been reported (Miret et al.,
2002). In all cases, as with the glucagon receptor and GLP-1
receptor, the pharmacology of the receptors is faithfully
transferred to the yeast all-be-it with a reduced affinity for
the ligands.
Extension of the technology to include many GPCRs or
other proteins, which may interact with the receptor in situ
(e.g. RAMPs and regulator of G protein signalling proteins),
would enable the observation of potential physiological
changes in receptor pharmacology. Additionally, the relative
simplicity of receptor expression within the yeast system
would allow the introduction of patient-specific mutations to
quantify their effects of ligand signalling potentially leading
to efficient screening of personalized drugs.
Figure 8
Comparison of GLP-1 receptor peptide ligands and relative bias factors. Sequences of the various peptide ligands for the GLP-1 receptor aligned
to the potent, natural agonist. Amino acids differing from those in GLP-1 are highlighted in grey. The relative (to GLP-1) bias factor was quantified
for each ligand as the change in log(τ/KA) ratio where a negative value indicates preference for the inhibitory, Gαi chimera. Statistical significance
was determined using one-way ANOVA with Bonferroni’s post-test with each data set compared with GLP-1 (**P < 0.01, ***P < 0.001). Data are
mean of 5–8 independent experiments ± SEM.
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